ClinicalTrials.gov

History of Changes for Study: NCT02082483
Coronary Artery Disease Screening in Kidney Transplant Candidates (CADScreening)
Latest version (submitted February 4, 2020) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 March 6, 2014 None (earliest Version on record)
2 September 12, 2014 Study Status
3 March 31, 2015 Recruitment Status, Study Status, Contacts/Locations and Oversight
4 March 29, 2016 Study Status and Sponsor/Collaborators
5 September 24, 2019 Recruitment Status, Study Status, Sponsor/Collaborators, Contacts/Locations, Study Design and Study Description
Show
Results Submission Events
6 February 4, 2020 Study Status, Outcome Measures, Document Section and Results
Comparison Format:

Scroll up to access the controls

Study NCT02082483
Submitted Date:  March 6, 2014 (v1)

Open or close this module Study Identification
Unique Protocol ID: H14-00141
Brief Title: Coronary Artery Disease Screening in Kidney Transplant Candidates (CADScreening)
Official Title: Pilot Study to Determine Feasibility of a Randomized Trial of Screening for Coronary Artery Disease in Kidney Transplant Candidates
Secondary IDs: MOP 133509 [Other Grant/Funding Number: Canadian Institutes of Health Research]
Open or close this module Study Status
Record Verification: March 2014
Overall Status: Not yet recruiting
Study Start: May 2014
Primary Completion: March 2017 [Anticipated]
Study Completion:
First Submitted: March 6, 2014
First Submitted that
Met QC Criteria:
March 6, 2014
First Posted: March 10, 2014 [Estimate]
Last Update Submitted that
Met QC Criteria:
March 6, 2014
Last Update Posted: March 10, 2014 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: University of British Columbia
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary:

Kidney transplant candidates are at very high risk for coronary artery disease (CAD). The optimal strategy to monitor and maintain the cardiac fitness of patients awaiting kidney transplantation is unknown. Currently patients undergo annual testing; however, screening for CAD may increase morbidity and mortality by:

  1. exposing patients to the risk of angiography and revascularization procedures
  2. delaying or excluding patients from life saving transplantation.

Before proceeding with a definitive study to determine whether screening is necessary, feasibility will be determined in this pilot study.

Detailed Description:

This pilot trial will determine the feasibility of a multi-center, randomized, parallel group definitive trial. Asymptomatic wait-listed patients will be randomized to routine screening for coronary artery diesease (CAD) (i.e. Myocardial Perfusion Scintigraphy (MPS) or Dobutamine Stress Echo (DSE)) as per the current standard of care versus selective screening based on symptoms. Patients enrolled in the pilot will be included in the definitive trial analysis. The pilot trial will include four Canadian centres. The definitive trial will aim to determine if a strategy of selective use of screening tests (i.e. Myocardial Perfusion Scintigraphy or Dobutamine Stress Echo) only in the presence of symptoms (i.e. chest pain, dyspnea etc) is non-inferior with respect to the composite endpoint of non-fatal MI and cardiac death compared to screening all asymptomatic wait-listed patients at regular intervals as described in transplant specific guidelines published by the National Kidney Foundation.

Currently there is no strong evidence for or against using routine cardiac screening of asymptomatic transplant patients, more evidence based randomized clinical trials are needed. This need is further highlighted by a number of factors such as: wait-listed patients are increasing in number and medical complexity; longer wait times and changing donor characteristics can increase CAD risk; wait-listed patients are at high risk for CAD but are commonly asymptomatic; the standard of care is not evidence based and is expensive; the current standard may be harmful. The study will determine feasibility of a definitive trial through the measures outlined under 'Outcome Measures'.

End stage renal disease (ESRD) patients wait-listed for kidney transplantation will be randomized to undergo selective screening for CAD, in which patients are only screened if they develop symptoms suggestive of CAD or the current standard of care that involves regular screening for CAD at fixed time intervals based on the presence of risk factors. Patients will remain on the pilot trial protocol until death, non-fatal MI, transplantation, permanent removal from the waiting list for any reason, or 24 months after enrolment in the pilot trial. During wait-listing, follow-up telephone interviews and chart reviews will be performed every six months. After transplantation, an in-person follow up visit and chart review will occur at the time of discharge from hospital, and a telephone interview and chart review will be performed 3 months after transplantation. Patients will be followed for 24 months from the date of enrolment. Patients who receive a kidney transplant during the study will be followed for 27 months.

For the pilot trial, descriptive analyses are planned. Feasibility will be summarized with proportions, rates, means, and medians as appropriate. Comparison of the definitive trial outcomes between treatment groups, will not be done at the end of the internal pilot as these patients will be included in the definitive trial. Analyses of enrolment rates and consent rates will be done after the enrolment phase of the pilot trial in late 2014. An interim analysis of protocol adherence is planned in mid 2016 in support of the definitive trial funding application in September, 2016.

Open or close this module Conditions
Conditions: End Stage Renal Disease
Coronary Artery Disease
Keywords: Kidney Transplant
Screening
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Not Applicable
Interventional Study Model: Parallel Assignment
Number of Arms: 2
Masking: None (Open Label)
Allocation: Randomized
Enrollment: 144 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Selective Screening
Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
Selective Screening
Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
No Intervention: Regular Screening
Patients randomized to regular screening will be tested as per the current standard described in guidelines published by the National Kidney Foundation (e.g. annually while wait-listed for transplantation). If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Protocol Adherence
[ Time Frame: Up to 27 months ]

Adherence will be defined by completion of the expected number of screening tests during follow up as per the 2005 National Kidney Foundation guidelines. For example, the expected number of screening tests in a diabetic patient who did not develop symptoms would be zero in the selective screening group, while the same patient would be expected to completed two screening tests if randomized to regular screening. Tests performed for clinical symptoms of CAD will be excluded from the determination of adherence.
2. Enrolment Rates
[ Time Frame: Measured after enrolment period of 6 months ]

The total number of subjects enrolled across all sites will be monitored monthly from the CRO, Ottawa Hospital Research Institute (OHRI), which issues the randomization scheme.
3. Consent Rate
[ Time Frame: Measured after enrolment period of 6 months ]

The percentage of patients willing to participate will be established at each site. Willingness to enrol in the study will be recorded on each patient's case report form along with the reason for any refusal to consent.
Secondary Outcome Measures:
1. Number of Participants with Cardiac Events
[ Time Frame: Up to 27 months ]

A composite outcome of cardiac death and non-fatal myocardial infarction will be looked at and adjudicated by a blinded clinical endpoints committee.
Other Outcome Measures:
1. Number of Transplant Events
[ Time Frame: Up to 24 months ]

Patient transplantation will be documented on the subject case report form.
2. Number of Wait List Holds or Removals
[ Time Frame: Up to 24 months ]

Indication for hold or removal will be measured as well.
3. Number of Health Care Encounters
[ Time Frame: Up to 27 months ]

The information captured will include outpatient, day care, and emergency room use (including any diagnostic testing and all medical and surgical interventions (i.e. use of thrombolytics, revascularization procedures), inpatient encounters and resource utilization (hospitalizations, procedural costs), physician consultations. Indirect patients costs (time off work, transportation costs), and quality of life (measured using the short-form 36 (SF36).
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  • age greater than 18 years
  • active on the deceased donor transplant waiting list

Exclusion Criteria:

  • patients not expected to require further screening for CAD prior to transplantation by the current standard of care. For example, a diabetic patient recently screened for CAD and expected to be transplanted <12 months from the start of the study would not require further screening according to current guidelines and would be ineligible
  • patients with signs or symptoms suggestive of active cardiac disease such as unstable coronary syndromes, de-compensated heart failure, uncontrolled arrhythmia, and severe valvular heart disease
  • patient who have been put "on hold" for transplantation due to a medical problem (e.g. an infection)
  • prior extra-renal transplant recipients
  • multi-organ transplant candidates (e.g. kidney pancreas transplant candidates)
  • patients with a planned living donor transplant
  • patients unable to provide informed consent
Open or close this module Contacts/Locations
Central Contact Person: John Gill, MD
Telephone: 604-682-2344 Ext. 69048
Email: jgill@providencehealth.bc.ca
Central Contact Backup: Jennie Chan, BSc
Telephone: 604-682-2344 Ext. 63135
Email: jchan2@providencehealth.bc.ca
Study Officials: John Gill, MD
Principal Investigator
St. Paul's Hospital
Locations: Canada, British Columbia
St. Paul's Hospital
Vancouver, British Columbia, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
Canada, Ontario
The Ottawa Hospital
Ottawa, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
Canada, Quebec
Royal Victoria Hospital
Montreal, Quebec, Canada
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services